References

Causes of vision loss worldwide, 1990–2010: a systematic analysis

10.1016/s2214-109x(13)70113-x · 2013 · External reference

Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review

10.1111/ceo.12696 · 2016 · External reference

Unresolved reference

External reference

Costs and quality of life in diabetic macular edema: Canadian Burden of Diabetic Macular Edema Observational Study (C-REALITY)

2014 · External reference

Comorbidity and health care visit burden in working-age commercially insured patients with diabetic macular edema

10.2147/opth.s114006 · 2016 · External reference

United States comparative costs and absenteeism of diabetic ophthalmic conditions

10.1080/00325481.2014.994468 · 2015 · External reference

Diabetic macular edema: pathophysiology and novel therapeutic targets

10.1016/j.ophtha.2015.03.024 · 2015 · External reference

Evidence-based guidelines for management of diabetic macular edema

10.1177/2474126419834711 · 2019 · External reference

Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE

10.1016/j.ophtha.2011.12.039 · 2012 · External reference

Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA)

10.1159/000458539 · 2017 · External reference

Diabetic retinopathy Preferred Practice Pattern®

10.1016/j.ophtha.2019.09.025 · 2020 · External reference

Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients

10.2147/opth.s151611 · 2018 · External reference

Compliance and adherence of patients with diabetic macular edema to intravitreal anti-vascular endothelial growth factor therapy in daily practice

10.1097/iae.0000000000001892 · 2018 · External reference

Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis

10.1001/jamaophthalmol.2015.4070 · 2016 · External reference

Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE

10.1016/j.ophtha.2013.02.034 · 2013 · External reference

Systematic review and mixed treatment comparison of intravitreal aflibercept with other therapies for diabetic macular edema (DME)

10.1186/s12886-015-0035-x · 2015 · External reference

The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema

10.1016/j.ophtha.2011.01.031 · 2011 · External reference

Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO study report 1)

10.2147/opth.s128509 · 2017 · External reference

Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment

10.1001/jamaophthalmol.2015.5346 · 2016 · External reference

Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial

10.1016/j.ophtha.2016.02.022 · 2016 · External reference

Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial

10.1001/jamaophthalmol.2017.6565 · 2018 · External reference

Early response to anti-vascular endothelial growth factor and two-year outcomes among eyes with diabetic macular edema in protocol T

10.1016/j.ajo.2018.07.030 · 2018 · External reference

Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema

10.1016/j.ophtha.2014.04.024 · 2014 · External reference

Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year Mead study

10.1097/iae.0000000000001004 · 2016 · External reference

Anti-integrin therapy for retinovascular diseases

10.1080/13543784.2020.1795639 · 2020 · External reference

Integrins: bidirectional, allosteric signaling machines

10.1016/s0092-8674(02)00971-6 · 2002 · External reference

10.1007/s00441-009-0834-6

10.1007/s00441-009-0834-6 · 2010 · External reference

Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases

10.1073/pnas.93.18.9764 · 1996 · External reference

Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent

2006 · External reference

Suppression and regression of choroidal neovascularization by systemic administration of an alpha5beta1 integrin antagonist

10.1124/mol.105.020941 · 2006 · External reference

Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats

10.1124/jpet.107.131656 · 2008 · External reference

The potent small molecule integrin antagonist THR-687 is a promising next-generation therapy for retinal vascular disorders

10.1016/j.exer.2018.11.022 · 2019 · External reference

The scoop on anti-integrin therapy for DME

2019 · External reference

Risuteganib-a novel integrin inhibitor for the treatment of non-exudative (dry) age-related macular degeneration and diabetic macular edema

10.1080/13543784.2020.1763953 · 2020 · External reference

Randomized, prospective, double-masked, controlled phase 2B trial on the safety and efficacy of Alg-1001 (Luminate)

2018 · External reference

Unresolved reference

2017 · External reference